{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:28:35Z","timestamp":1790497715036,"version":"4.1.0"},"reference-count":138,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.aohep.2019.09.009","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T05:32:56Z","timestamp":1572759176000},"page":"5-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies"],"prefix":"10.1016","volume":"19","author":[{"given":"Alessio","family":"Gerussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"D\u2019Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cristoferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Elizabeth","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2019.09.009_bib0695","series-title":"Sherlock's diseases of the liver and biliary system","first-page":"1","author":"Dooley","year":"2011"},{"key":"10.1016\/j.aohep.2019.09.009_bib0700","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib0705","first-page":"167","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"145","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib0710","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib0715","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: the FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.aohep.2019.09.009_bib0720","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6\u03b1-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.aohep.2019.09.009_bib0725","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2019.09.009_bib0730","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.aohep.2019.09.009_bib0735","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib0740","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2019.09.009_bib0745","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib0750","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","article-title":"Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement","volume":"60","author":"Nakanuma","year":"2010","journal-title":"Pathol Int"},{"key":"10.1016\/j.aohep.2019.09.009_bib0755","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of Tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.aohep.2019.09.009_bib0760","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0168-8278(18)30426-4","article-title":"LBO-007 \u2013 early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: an interim analysis of an ongoing phase 2 study","volume":"68","author":"Schramm","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib0765","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/S0168-8278(17)30608-6","article-title":"A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis","volume":"66","author":"Erstad","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib0770","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009098","article-title":"A nontumorigenic variant of FGF19 treats cholestatic liver diseases","volume":"6","author":"Luo","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib0775","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.aohep.2019.09.009_bib0780","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.28257","article-title":"Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice","volume":"63","author":"Zhou","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib0785","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.aohep.2019.09.009_bib0790","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib0795","doi-asserted-by":"crossref","first-page":"E1369","DOI":"10.1073\/pnas.1202464109","article-title":"Protection from liver fibrosis by a peroxisome proliferator-activated receptor \u03b4 agonist","volume":"109","author":"Iwaisako","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.aohep.2019.09.009_bib0800","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1002\/hep.25919","article-title":"Liver X receptor \u03b2 and peroxisome proliferator-activated receptor \u03b4 regulate cholesterol transport in murine cholangiocytes","volume":"56","author":"Xia","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib0805","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/nm.2048","article-title":"PPAR-\u0394 senses and orchestrates clearance of apoptotic cells to promote tolerance","volume":"15","author":"Mukundan","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib0810","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib0815","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib0820","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.aohep.2019.09.009_bib0825","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1751-2980.2012.00574.x","article-title":"Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy","volume":"13","author":"Han","year":"2012","journal-title":"J Dig Dis"},{"key":"10.1016\/j.aohep.2019.09.009_bib0830","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"Open Cardiovasc Med J"},{"key":"10.1016\/j.aohep.2019.09.009_bib0835","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2019.09.009_bib0840","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2019.09.009_bib0845","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib0850","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1016\/S0618-8278(19)30226-9","article-title":"LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment","volume":"70","author":"J\u00f6rn","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib0855","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","article-title":"The immunobiology and pathophysiology of primary biliary cirrhosis","volume":"8","author":"Hirschfield","year":"2013","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"10.1016\/j.aohep.2019.09.009_bib0860","article-title":"Azathioprine for primary biliary cirrhosis","author":"Gong","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.aohep.2019.09.009_bib0865","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0168-8278(98)80254-7","article-title":"Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study","volume":"29","author":"Wolfhagen","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib0870","doi-asserted-by":"crossref","DOI":"10.1097\/01.mcg.0000177235.36640.21","article-title":"Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid","volume":"39","author":"Treiber","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.aohep.2019.09.009_bib0875","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM199005173222003","article-title":"A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis","volume":"322","author":"Wiesner","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib0880","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.20897","article-title":"Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis","volume":"42","author":"Combes","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib0885","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2019.04.005","article-title":"Therapeutic trials of biologics in primary biliary cholangitis: an open label study of abatacept and review of the literature","volume":"101","author":"Bowlus","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.aohep.2019.09.009_bib0890","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2019.09.009_bib0895","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib0900","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib0905","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.23238","article-title":"B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-\u03b2 receptor II dominant negative mice","volume":"50","author":"Moritoki","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib0910","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.aohep.2019.09.009_bib0915","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/hep.30099","article-title":"Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial","volume":"70","author":"Khanna","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib0920","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/eji.201344270","article-title":"Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis","volume":"44","author":"Carbone","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.aohep.2019.09.009_bib0925","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib0930","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2019.09.009_bib0935","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","article-title":"Mechanisms of disease: inflammatory bowel diseases","volume":"94","author":"Ramos","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.aohep.2019.09.009_bib0940","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants","volume":"360","author":"Hirschfield","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib0945","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib0950","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/hep.26067","article-title":"Therapeutic effect of cytotoxic T lymphocyte antigen 4\/immunoglobulin on a murine model of primary biliary cirrhosis","volume":"57","author":"Dhirapong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib0955","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: a review in rheumatoid arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.aohep.2019.09.009_bib0960","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.aohep.2019.09.009_bib0965","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.00212","article-title":"Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists","volume":"10","author":"P\u00e9rez-Jeldres","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.aohep.2019.09.009_bib0970","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMct0807960","article-title":"Treatment of non-small-cell lung cancer with erlotinib or gefitinib","volume":"364","author":"Cataldo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib0975","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib0980","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J Clin Investig"},{"key":"10.1016\/j.aohep.2019.09.009_bib0985","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbadis.2017.07.026","article-title":"Pathogenesis of biliary fibrosis","volume":"1864","author":"Pinzani","year":"2018","journal-title":"Biochim Biophys Acta \u2013 Mol Basis Dis"},{"key":"10.1016\/j.aohep.2019.09.009_bib0990","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri1312","article-title":"NOX enzymes and the biology of reactive oxygen","volume":"4","author":"Lambeth","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.aohep.2019.09.009_bib0995","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00281-008-0127-2","article-title":"NOX enzymes in immuno-inflammatory pathologies","volume":"30","author":"Krause","year":"2008","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1000","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/hep.25938","article-title":"Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent","volume":"56","author":"Aoyama","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib1005","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.04.009","article-title":"Hepatocyte nicotinamide adenine dinucleotide phosphate reduced oxidase 4 regulates stress signaling, fibrosis, and insulin sensitivity during development of steatohepatitis in mice","volume":"149","author":"Bettaieb","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2019.09.009_bib1010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S0618-8278(19)30002-7","article-title":"GS-02-efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: interim efficacy results of a phase 2 clinical trial","volume":"70","author":"Dalekos","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1015","first-page":"1","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome","volume":"113","author":"Harms","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/apt.15060","article-title":"Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades","volume":"49","author":"Harms","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2019.09.009_bib1025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cld.2018.03.006","article-title":"Individualizing care: management beyond medical therapy","volume":"22","author":"Cristoferi","year":"2018","journal-title":"Clin Liver Dis"},{"issue":"9","key":"10.1016\/j.aohep.2019.09.009_bib1030","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.autrev.2018.02.013","article-title":"Support of precision medicine through risk-stratification in autoimmune liver diseases \u2013 histology, scoring systems, and non-invasive markers","volume":"17","author":"Bossen","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.aohep.2019.09.009_bib1035","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1111\/liv.13221","article-title":"Gamma-glutamyltransferase\u2014friend or foe within?","volume":"36","author":"Kunutsor","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2019.09.009_bib1040","series-title":"Harrison's principles of internal medicine","author":"Kasper","year":"2015"},{"key":"10.1016\/j.aohep.2019.09.009_bib1045","first-page":"1","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"1253","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1050","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S0618-8278(19)30229-4","article-title":"LBO-05-Bezafibrate improves the effect of obeticholic acid on cholestasis in patients with primary biliary cholangitis","volume":"70","author":"Smets","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1055","unstructured":"Intercept announces NASH and PBC program updates; n.d. http:\/\/ir.interceptpharma.com\/node\/12241\/pdf."},{"key":"10.1016\/j.aohep.2019.09.009_bib1060","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis \u2013 a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1065","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jhep.2014.02.006","article-title":"Characterization of animal models for primary sclerosing cholangitis (PSC)","volume":"60","author":"Fickert","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1070","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S0618-8278(19)30022-2","article-title":"PS-016-prospective evaluation of serum alkaline phosphatase variability and prognostic utility in primary sclerosing cholangitis using controlled clinical trial data","volume":"70","author":"Trivedi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1075","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2019.09.009_bib1080","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1085","first-page":"1","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib1090","first-page":"1254A","article-title":"The AESOP trial: a randomized, double-blind, placebo-controlled, phase 2 study of obeticholic acid in patients with primary sclerosing cholangitis","volume":"66","author":"Kowdley","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2019.09.009_bib1095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41575-019-0110-5","article-title":"Better end points needed in primary sclerosing cholangitis trials","volume":"16","author":"Gerussi","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1100","first-page":"2018","article-title":"NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a nebulous matter","author":"Tabibian","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1105","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1194\/jlr.M005546","article-title":"Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR\/RXR-dependent and independent mechanisms","volume":"51","author":"Cai","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.aohep.2019.09.009_bib1110","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hep.24047","article-title":"Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells","volume":"53","author":"He","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib1115","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/liv.13698","article-title":"Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents","volume":"38","author":"Yu","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2019.09.009_bib1120","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1097\/MCG.0000000000000591","article-title":"Combination therapy of all-trans retinoic acid with ursodeoxycholic acid in patients with primary sclerosing cholangitis: a human pilot study","volume":"51","author":"Assis","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1125","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/jhbp.281","article-title":"Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis","volume":"22","author":"Mizuno","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.aohep.2019.09.009_bib1130","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s00535-010-0204-x","article-title":"Bezafibrate for the treatment of primary sclerosing cholangitis","volume":"45","author":"Mizuno","year":"2010","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1135","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","article-title":"Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French\u2013Spanish experience","volume":"42","author":"Lemoinne","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1140","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib1145","doi-asserted-by":"crossref","first-page":"S633","DOI":"10.1093\/ecco-jcc\/jjy011","article-title":"Past, present and future of therapeutic interventions targeting leukocyte trafficking in inflammatory bowel disease","volume":"12","author":"Pan\u00e9s","year":"2018","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.aohep.2019.09.009_bib1150","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1084\/jem.20041035","article-title":"Hepatic endothelial CCL25 mediates the recruitment of CCR9 + gut-homing lymphocytes to the liver in primary sclerosing cholangitis","volume":"200","author":"Eksteen","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib1155","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1053\/jhep.2001.24231","article-title":"MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease)","volume":"33","author":"Grant","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib1160","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.gastro.2015.10.046","article-title":"Leukocyte trafficking to the small intestine and colon","volume":"150","author":"Habtezion","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2019.09.009_bib1165","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jhep.2015.12.002","article-title":"Gut\u2013liver immunity","volume":"64","author":"Trivedi","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1170","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","article-title":"Targeting the gut\u2013liver axis in liver disease","volume":"67","author":"Wiest","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1175","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","author":"Lynch","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1180","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.crohns.2012.09.016","article-title":"Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study","volume":"7","author":"Herrlinger","year":"2013","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.aohep.2019.09.009_bib1185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bmcl.2005.10.011","article-title":"Biphenyl-4-ylcarbamoyl thiophene carboxylic acids as potent DHODH inhibitors","volume":"16","author":"Leban","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.aohep.2019.09.009_bib1190","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/ibd.21264","article-title":"4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease","volume":"16","author":"Fitzpatrick","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.aohep.2019.09.009_bib1195","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/gutjnl-2016-312354","article-title":"Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner","volume":"67","author":"Trivedi","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2019.09.009_bib1200","doi-asserted-by":"crossref","first-page":"e015081","DOI":"10.1136\/bmjopen-2016-015081","article-title":"Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): a single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol","volume":"7","author":"Arndtz","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.aohep.2019.09.009_bib1205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2013.08.006","article-title":"Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ","volume":"46","author":"Invernizzi","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.aohep.2019.09.009_bib1210","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2019.09.009_bib1215","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1056\/NEJMra1600266","article-title":"The human intestinal microbiome in health and disease","volume":"375","author":"Lynch","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib1220","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/apt.14397","article-title":"Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease","volume":"47","author":"Woodhouse","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2019.09.009_bib1225","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0037-1608801","article-title":"The microbiome in primary sclerosing cholangitis: current evidence and potential concepts","volume":"37","author":"Hov","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.aohep.2019.09.009_bib1230","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis \u2013 a pilot study","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2019.09.009_bib1235","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2008.14","article-title":"Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study","volume":"104","author":"Silveira","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1240","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J Gastrointest Liver Dis"},{"key":"10.1016\/j.aohep.2019.09.009_bib1245","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/MJT.0000000000000102","article-title":"Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis","volume":"24","author":"Tabibian","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.aohep.2019.09.009_bib1250","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.12.019","article-title":"Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent clostridium difficile infection","volume":"156","author":"Hvas","year":"2019","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.aohep.2019.09.009_bib1255","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1260","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrmicro2853","article-title":"Going viral: next-generation sequencing applied to phage populations in the human gut","volume":"10","author":"Reyes","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1265","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrgastro.2014.188","article-title":"Mycobiota in gastrointestinal diseases","volume":"12","author":"Mukherjee","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1270","article-title":"Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis","author":"Lemoinne","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2019.09.009_bib1275","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-019-0965-1","article-title":"A new genomic blueprint of the human gut microbiota","volume":"568","author":"Almeida","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.aohep.2019.09.009_bib1280","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1038\/nmicrobiol.2015.16","article-title":"Microbiome: ecology of stable gut communities","volume":"1","author":"McNally","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1285","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41598-018-37143-z","article-title":"The gut microbiota heterogeneity and assembly changes associated with the IBD","volume":"9","author":"Sun","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.aohep.2019.09.009_bib1290","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2019.09.009_bib1295","first-page":"1","article-title":"Nanoparticle-based approaches to immune tolerance for the treatment of autoimmune diseases","volume":"1","author":"Serra","year":"2018","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.aohep.2019.09.009_bib1300","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1021\/acsnano.8b09655","article-title":"Dexamethasone conjugation to biodegradable avidin-nucleic-acid-nano-assemblies promotes selective liver targeting and improves therapeutic efficacy in an autoimmune hepatitis murine model","volume":"13","author":"Violatto","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.aohep.2019.09.009_bib1305","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nature16962","article-title":"Expanding antigen-specific regulatory networks to treat autoimmunity","volume":"530","author":"Clemente-Casares","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.aohep.2019.09.009_bib1310","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41467-019-09893-5","article-title":"Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines","volume":"10","author":"Umeshappa","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.aohep.2019.09.009_bib1315","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/liv.13744","article-title":"Time for the dawn of multimodal therapies and the dusk for mono-therapeutic trials for cholestatic liver diseases?","volume":"38","author":"Wagner","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2019.09.009_bib1320","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.aohep.2019.09.009_bib1325","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11901-019-00454-4","article-title":"Future medical treatment of PSC","author":"Krones","year":"2019","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.aohep.2019.09.009_bib1330","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2012.02.009","article-title":"Personal omics profiling reveals dynamic molecular and medical phenotypes","volume":"148","author":"Chen","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.aohep.2019.09.009_bib1335","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41540-017-0009-0","article-title":"Integrating personalized gene expression profiles into predictive disease-associated gene pools","volume":"3","author":"Menche","year":"2017","journal-title":"NPJ Syst Biol Appl"},{"key":"10.1016\/j.aohep.2019.09.009_bib1340","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrg.2018.4","article-title":"Integrative omics for health and disease","volume":"19","author":"Karczewski","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.aohep.2019.09.009_bib1345","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1038\/s41467-018-06921-8","article-title":"Multi-omic tumor data reveal diversity of molecular mechanisms that correlate with survival","volume":"9","author":"Ramazzotti","year":"2018","journal-title":"Nat Commun"},{"issue":"7747","key":"10.1016\/j.aohep.2019.09.009_bib1350","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-019-0987-8","article-title":"Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma","volume":"567","author":"Jiang","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.aohep.2019.09.009_bib1355","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib1360","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41591-019-0414-6","article-title":"A longitudinal big data approach for precision health","volume":"25","author":"Sch\u00fcssler-Fiorenza Rose","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.aohep.2019.09.009_bib1365","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41586-019-1195-2","article-title":"Single-cell transcriptomic analysis of Alzheimer's disease","volume":"570","author":"Mathys","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.aohep.2019.09.009_bib1370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-43699-1","article-title":"Common functional alterations identified in blood transcriptome of autoimmune cholestatic liver and inflammatory bowel diseases","volume":"9","author":"Ostrowski","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.aohep.2019.09.009_bib1375","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/1751-2980.12787","article-title":"Precision medicine in primary biliary cholangitis","volume":"20","author":"Ronca","year":"2019","journal-title":"J Dig Dis"},{"key":"10.1016\/j.aohep.2019.09.009_bib1380","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.dld.2016.05.023","article-title":"Toward precision medicine in primary biliary cholangitis","volume":"48","author":"Carbone","year":"2016","journal-title":"Dig Liver Dis"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119322604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119322604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:40:09Z","timestamp":1761648009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119322604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":138,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1665268119322604"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2019.09.009","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2019.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}